Dr. Ribas, along with James P. Allison, Ph.D., Drew M. Pardoll, M.D., Ph.D., and Cassian Yee, M.D., is leading the SU2C-CRI Cancer Immunology Translational Research Dream Team, which is performing comprehensive experiments aimed at improving immunotherapy’s ability to improve patient outcomes.
Among the Dream Team’s activities are: systematically assessing the expression of candidate molecules and pathways in the tumor microenvironment before and after checkpoint blockade immunotherapy; using a combination of sequencing techniques to assess checkpoint blockade-induced T-cell responses to tumor-specific neo-antigens; working to improve the quality of cancer-specific T cell generated for adoptive cell transfer (ACT) therapy; evaluating the effect of epigenetic therapy on immunotherapy and assessing the combination of checkpoint blockade immunotherapy and ACT in patients.
Dr. Ribas is the 2018 recipient of the AACR-CRI Lloyd J. Old Award in Cancer Immunology.
Projects and Grants
Immunologic checkpoint blockade and adoptive cell transfer in cancer therapy
University of California, Los Angeles | All Cancers, Kidney Cancer, Lung Cancer, Melanoma, Prostate Cancer | 2013
Let's spread the word about Immunotherapy! Click to share this page with your community.